
Stonegate Capital Partners Updates Coverage on Cingulate Inc., Highlights CMC-Driven Path Forward
Stonegate Capital Partners updates coverage on Cingulate Inc., noting that the FDA's Complete Response Letter for CTx-1301 focuses on CMC issues rather than safety or efficacy, and the company's strong cash position supports the resubmission process.
Read full story























